RALPH HRUBAN, M.D.
Medical Practice at Wolfe St, Baltimore, MD
License number
Maryland D34620
Category
Medical Practice
Type
Anatomic Pathology & Clinical Pathology
Address
Address
600 N Wolfe St, Baltimore, MD 21287
Phone
(410) 955-2660
Professional information
Genes Frequently Altered In Pancreatic Neuroendocrine Tumors
US Patent:
2014004, Feb 13, 2014
Filed:
Jan 4, 2012
Appl. No.:
13/977810
Inventors:
Bert Vogelstein - Baltimore MD, US
Kenneth W. Kinzler - Baltimore MD, US
Victor Velculescu - Dayton MD, US
Luis Diaz - Ellicott City MD, US
Nikolas Papadopoulos - Towson MD, US
Yuchen Jiao - Culombia MD, US
Ralph Hruban - Baltimore MD, US
Kenneth W. Kinzler - Baltimore MD, US
Victor Velculescu - Dayton MD, US
Luis Diaz - Ellicott City MD, US
Nikolas Papadopoulos - Towson MD, US
Yuchen Jiao - Culombia MD, US
Ralph Hruban - Baltimore MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
C12Q 1/68
US Classification:
514291, 506 2, 435 71, 536 231, 536 2433
Abstract:
Pancreatic Neuroendocrine Tumors (PanNETs) are a rare but clinically important form of pancreatic neoplasia. To explore the genetic basis of PanNETs, we determined the exomic sequences of ten non-familial PanNETs and then screened the most commonly mutated genes in 58 additional PanNETs. Remarkably, the most frequently mutated genes specify proteins implicated in chromatin remodeling: 44% of the tumors had somatic inactivating mutations in MEN-1, which encodes menin, a component of a histone methyltransferase complex; and 43% had mutations in genes encoding either of the two subunits of a transcription/chromatin remodeling complex consisting of DAXX (death-domain associated protein) and ATRX (alpha thalassemia/mental retardation syndrome X-linked). Clinically, mutations in the MEN1 and DAXX/ATRX genes were associated with better prognosis. We also found mutations in genes in the mTOR (mammalian target of rapamycin) pathway in 14% of the tumors, a finding that could potentially be used to stratify patients for treatment with mTOR inhibitors.
Pathways Underlying Pancreatic Tumorigenesis And An Hereditary Pancreatic Cancer Gene
US Patent:
2012011, May 10, 2012
Filed:
Sep 3, 2009
Appl. No.:
13/060453
Inventors:
Bert Vogelstein - Baltimore MD, US
Kenneth W. Kinzler - Baltimore MD, US
D. Williams Parsons - Ellicott City MD, US
Sian Jones - Baltimore MD, US
Xiaosong Zhang - Baltimore MD, US
Jimmy Cheng-Ho Lin - Baltimore MD, US
Rebecca J. Leary - Baltimore MD, US
Philipp Angenendt - Hamburg, DE
Nickolas Papadopoulos - Towson MD, US
Victor Velculescu - Dayton MD, US
Giovanni Parmigiani - Brookline MA, US
Rachel Karchin - Towson MD, US
Scott Kern - Hunt Valley MD, US
Ralph Hruban - Baltimore MD, US
James R. Eshleman - Lutherville MD, US
Michael Goggins - Baltimore MD, US
Alison Klein - Baltimore MD, US
Kenneth W. Kinzler - Baltimore MD, US
D. Williams Parsons - Ellicott City MD, US
Sian Jones - Baltimore MD, US
Xiaosong Zhang - Baltimore MD, US
Jimmy Cheng-Ho Lin - Baltimore MD, US
Rebecca J. Leary - Baltimore MD, US
Philipp Angenendt - Hamburg, DE
Nickolas Papadopoulos - Towson MD, US
Victor Velculescu - Dayton MD, US
Giovanni Parmigiani - Brookline MA, US
Rachel Karchin - Towson MD, US
Scott Kern - Hunt Valley MD, US
Ralph Hruban - Baltimore MD, US
James R. Eshleman - Lutherville MD, US
Michael Goggins - Baltimore MD, US
Alison Klein - Baltimore MD, US
Assignee:
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
C12Q 1/68, C40B 20/00, C07H 21/04
US Classification:
506 2, 435 611, 536 2431, 536 2433
Abstract:
There are currently few therapeutic options for patients with pancreatic cancers and new insights into the pathogenesis of this lethal disease are urgently needed. To this end, we performed a comprehensive analysis of the genes altered in 24 pancreatic tumors. First, we determined the sequences of 23,781 transcripts, representing 20,583 protein-encoding genes, in DNA from these tumors. Second, we searched for homozygous deletions and amplifications using microarrays querying ˜one million single nucleotide polymorphisms in each sample. Third, we analyzed the transcriptomes of the same samples using SAGE and next-generation sequencing-by-synthesis technologies. We found that pancreatic cancers contain an average of 63 genetic alterations, of which 49 are point mutations, 8 are homozygous deletions, and 6 are amplifications. Further analyses revealed a core set of 12 regulatory processes or pathways that were each genetically altered in 70% to 100% of the samples. The data suggest that dysregulation of this core set of pathways is responsible for the major features of pancreatic tumorigenesis.
Ralph Harvey Hruban, Baltimore MD
Specialties:
Pathology, Anatomic Pathology, Anatomic Pathology & Clinical Pathology
Work:
The Johns Hopkins Hospital
600 N Wolfe St, Baltimore, MD 21287
600 N Wolfe St, Baltimore, MD 21287
Education:
Johns Hopkins University (1985)
Mesothelin Vaccines And Model Systems
US Patent:
2012007, Mar 29, 2012
Filed:
Nov 10, 2011
Appl. No.:
13/293357
Inventors:
Chien-Fu Hung - Timonium MD, US
Elizabeth JAFFEE - Lutherville MD, US
Ralph HRUBAN - Baltimore MD, US
Elizabeth JAFFEE - Lutherville MD, US
Ralph HRUBAN - Baltimore MD, US
Assignee:
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
A61K 39/00, A61P 37/04, A61P 35/00, A61K 38/19, C12N 1/21
US Classification:
424 851, 4241851, 4352523
Abstract:
Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.
Dr. Ralph H Hruban, Baltimore MD - MD (Doctor of Medicine)
Specialties:
Anatomic Pathology
Address:
Baltimore Office
600 N Wolfe St, Baltimore 21287
(410) 955-3071 (Phone)
John Hopkins Surgical Pathology
401 N Broadway St STE 2242, Baltimore 21287
(410) 955-5043 (Phone)
600 N Wolfe St, Baltimore 21287
(410) 955-3071 (Phone)
John Hopkins Surgical Pathology
401 N Broadway St STE 2242, Baltimore 21287
(410) 955-5043 (Phone)
Certifications:
Anatomic Pathology, 1990
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Baltimore Office
600 N Wolfe St, Baltimore 21287
John Hopkins Surgical Pathology
401 N Broadway St STE 2242, Baltimore 21287
Johns Hopkins Bayview Medical Center
4940 Eastern Ave, Baltimore 21224
600 N Wolfe St, Baltimore 21287
John Hopkins Surgical Pathology
401 N Broadway St STE 2242, Baltimore 21287
Johns Hopkins Bayview Medical Center
4940 Eastern Ave, Baltimore 21224
Education:
Medical School
Johns Hopkins University School Of Medicine
Graduated: 1985
The Johns Hopkins Hospital
Graduated: 1986
Graduated: 1990
Meml Sloan Kettering Canc C
Graduated: 1989
Johns Hopkins University School Of Medicine
Graduated: 1985
The Johns Hopkins Hospital
Graduated: 1986
Graduated: 1990
Meml Sloan Kettering Canc C
Graduated: 1989
Mesothelin Vaccines And Model Systems
US Patent:
2009016, Jun 25, 2009
Filed:
Sep 15, 2008
Appl. No.:
12/210604
Inventors:
Elizabeth Jaffee - Lutherville MD, US
Chien-Fu Hung - Brookville MD, US
Ralph Hruban - Baltimore MD, US
Chien-Fu Hung - Brookville MD, US
Ralph Hruban - Baltimore MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
A61B 10/00, C12Q 1/68, C12N 5/10, A01K 67/027
US Classification:
800 3, 435 6, 435354, 800 10
Abstract:
Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.
Mesothelin Vaccines And Model Systems And Control Of Tumors
US Patent:
2009011, Apr 30, 2009
Filed:
Mar 17, 2008
Appl. No.:
12/049763
Inventors:
T.C. WU - Stevenson MD, US
Chien-Fu Hung - Timonium MD, US
Elizabeth Jaffee - Lutherville MD, US
Ralph Hruban - Baltimore MD, US
Chien-Fu Hung - Timonium MD, US
Elizabeth Jaffee - Lutherville MD, US
Ralph Hruban - Baltimore MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
A61K 39/00
US Classification:
4242771, 4241841
Abstract:
Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.
Mesothelin Vaccines And Model Systems
US Patent:
2005017, Aug 11, 2005
Filed:
Jul 14, 2003
Appl. No.:
10/618088
Inventors:
Elizabeth Jaffee - Lutherville MD, US
Chien-Fu Hung - Timonium MD, US
Ralph Hruban - Baltimore MD, US
Chien-Fu Hung - Timonium MD, US
Ralph Hruban - Baltimore MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
A61K039/00
US Classification:
424185100
Abstract:
Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.
Mesothelin Vaccines And Model Systems
US Patent:
2014005, Feb 20, 2014
Filed:
Oct 1, 2013
Appl. No.:
14/042812
Inventors:
Chien-Fu Hung - Timonium MD, US
Ralph Hruban - Baltimore MD, US
Ralph Hruban - Baltimore MD, US
Assignee:
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
C07K 7/06
US Classification:
4241851
Abstract:
Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.
Diagnostic Method Using Palb2
US Patent:
2012003, Feb 9, 2012
Filed:
Mar 5, 2010
Appl. No.:
13/254610
Inventors:
Bert Vogelstein - Baltimore MD, US
Kenneth W. Kinzler - Baltimore MD, US
D. Williams Parsons - Ellicott City MD, US
Sian Jones - Baltimore MD, US
Scott Kern - Hunt Valley MD, US
Ralph Hruban - Baltimore MD, US
James R. Eshleman - Lutherville MD, US
Michael Goggins - Baltimore MD, US
Alison Klein - Baltimore MD, US
Manuel Hidalgo - Baltimore MD, US
Victor E. Velculescu - Dayton MD, US
Kenneth W. Kinzler - Baltimore MD, US
D. Williams Parsons - Ellicott City MD, US
Sian Jones - Baltimore MD, US
Scott Kern - Hunt Valley MD, US
Ralph Hruban - Baltimore MD, US
James R. Eshleman - Lutherville MD, US
Michael Goggins - Baltimore MD, US
Alison Klein - Baltimore MD, US
Manuel Hidalgo - Baltimore MD, US
Victor E. Velculescu - Dayton MD, US
Assignee:
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
A61K 33/24, A61P 35/00, C40B 20/08, G01N 33/577, G01N 33/566, C12Q 1/68
US Classification:
424649, 435 723, 435 612, 435 611, 506 6
Abstract:
The present invention provides a method for detecting mutations in the PALB2 gene in pancreatic cancer patients and in individuals having a family history of pancreatic cancer. Methods are also provided for diagnosing a predisposition to pancreatic cancer, for predicting a patient's response to pancreatic cancer therapies, and for treating pancreatic cancer, based on presence of a PALB2 mutation or abberant PALB2 gene expression in a patient.